keyword
MENU ▼
Read by QxMD icon Read
search

Indolent lymphoma

keyword
https://www.readbyqxmd.com/read/29149251/parental-age-and-risk-of-lymphoid-neoplasms
#1
Gunnar Larfors, Ingrid Glimelius, Sandra Eloranta, Karin E Smedby
High parental age at childbirth has repeatedly been linked to childhood malignancies, while few studies have focused on the offspring's risk of adult cancer. In this population-based case-control study, we identified 32,000 patients with lymphoid neoplasms, diagnosed at ages 0-79 years during the period 1987-2011, and 160,000 matched controls in Sweden. Using prospectively registered data on their first-degree relatives, we evaluated the impact of parental age on the risk of lymphoid neoplasms by subtype. Overall, each 5-year increment in maternal age was associated with a 3% increase in incidence of offspring lymphoid neoplasms (hazard ratio = 1...
November 15, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/29143359/indolent-t-lymphoblastic-proliferation-concomitant-to-acinic-cell-carcinoma-mimicking-t-lymphoblastic-lymphoma-case-report-and-literature-review
#2
Hajime Yasuda, Miyuki Tsutsui, Yasunori Ota, Masaru Tanaka, Norio Komatsu
Indolent T-lymphoblastic proliferation (iT-LBP) is a non-clonal benign condition showing extrathymic proliferation of T-lymphoblasts positive for CD3, CD4, CD8, and TdT. Isolated iT-LBP has been observed, but the majority of iT-LBP have been seen in conjunction with other disorders including Castleman disease, hepatocellular carcinoma, follicular dendritic cell tumors, angioimmunoblastic T-cell lymphoma, myasthenia gravis, and acinic cell carcinoma (ACC). The clinical course of iT-LBP is indolent, and no therapy is usually required...
November 15, 2017: Histopathology
https://www.readbyqxmd.com/read/29143105/application-of-dwibs-in-malignant-lymphoma-correlation-between-adc-values-and-ki-67-index
#3
Mengtian Sun, Jingliang Cheng, Yong Zhang, Jie Bai, Feifei Wang, Yun Meng, Zhenqian Li
OBJECTIVES: We investigated the correlation between the apparent diffusion coefficient (ADC) and Ki-67 index using diffusion-weighted whole-body imaging with background body signal suppression (DWIBS), and their utility in evaluating malignant lymphoma cell proliferation. MATERIALS AND METHODS: Seventy-four patients with malignant lymphoma underwent DWIBS within 1 week before pathological confirmation. The ADC value was measured at the site of the pathological examination, and specimens were also stained with Ki-67...
November 15, 2017: European Radiology
https://www.readbyqxmd.com/read/29127587/copanlisib-first-global-approval
#4
Anthony Markham
Bayer are developing copanlisib (Aliqopa™)-a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor-as a treatment for various haematological and solid malignancies. The US FDA has granted copanlisib accelerated approval for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies based on the results of a phase II trial. Phase III trials are underway evaluating copanlisib as treatment for relapsed/refractory diffuse large B-cell lymphoma and in combination with rituximab or rituximab-based chemotherapy or standard immunochemotherapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma...
November 10, 2017: Drugs
https://www.readbyqxmd.com/read/29121713/health-related-quality-of-life-in-non-hodgkin-lymphoma-survivors-a-prospective-cohort-study
#5
Danbee Kang, Juhee Cho, ImRyung Kim, Mi Kyung Kim, Won Seog Kim, Seok Jin Kim
Purpose: We evaluated health-related quality of life (HRQOL) in long-term survivors of indolent and aggressive non-Hodgkin lymphoma (NHL). Materials and methods: The HRQOL was assessed by the European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire Core 30 (EORTC QLQ-C30) at diagnosis in NHL patients between 2008 and 2011, and follow-up evaluation was conducted from June 2014 to Feb 2015 using EORTC QLQ-C30 and the quality of life in cancer survivors (QOL-CS) questionnaire...
November 9, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29118233/hairy-cell-leukemia-version-2-2018-nccn-clinical-practice-guidelines-in-oncology
#6
William G Wierda, John C Byrd, Jeremy S Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E Coutre, Randall S Davis, Christopher D Fletcher, Brian Hill, Brad S Kahl, Manali Kamdar, Lawrence D Kaplan, Nadia Khan, Thomas J Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D Zelenetz, Mary A Dwyer, Hema Sundar
Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entity separate from HCLvariant (HCLv), which is associated with a more aggressive disease course and may not respond to standard HCL therapies. Somatic hypermutation in the IGHV gene is present in most patients with HCL. The BRAF V600E mutation has been reported in most patients with classic HCL but not in those with other B-cell leukemias or lymphomas...
November 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29114604/effectiveness-of-low-dose-radiation-for-primary-cutaneous-anaplastic-large-cell-lymphoma
#7
Grace L Smith, Madeleine Duvic, Zeinab Abou Yehia, Pamela Allen, Naveen Garg, Tina Suki, Sarah A Milgrom, Chelsea C Pinnix, Yasuhiro Oki, Joseph D Khoury, Bouthaina S Dabaja
Purpose: Primary cutaneous anaplastic large cell lymphoma (pcALCL) is conventionally treated with radiation therapy (RT) doses ≥30 GGy, but effectiveness of lower doses is unclear. We compared responses after a range of RT doses for pcALCL. Methods and materials: From 1999 through 2015, 45 lesions in 21 patients met clinicopathologic pcALCL diagnostic criteria and were treated with RT (<20 Gy, 20-29 Gy, or ≥30 Gy dose). Complete clinical (CR) and partial responses (PR) were compared by dose using Fisher exact test...
July 2017: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/29108238/sites-of-extranodal-involvement-are-prognostic-in-patients-with-stage-1-follicular-lymphoma
#8
Aditi Shastri, Murali Janakiram, Ioannis Mantzaris, Yiting Yu, Jaime S Londono, Amit K Verma, Stefan K Barta
Objectives: Follicular lymphoma (FL) is the most common indolent B cell lymphoma in the United States and a quarter of patients present with stage I disease. The objective of this study was to examine if primary site of disease influences survival in early stage lymphoma. Results: The most common extranodal primary sites were the integumentary system (8%), followed by the GI tract (6.4%) and head & neck (5.6%). We stratified patients into a pre-rituximab era (1983-1998) and the rituximab era (1999-2011)...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29103980/extranodal-marginal-zone-lymphoma-of-the-central-nervous-system
#9
REVIEW
Adanma Ayanambakkam, Sami Ibrahimi, Khalid Bilal, Mohamad A Cherry
Extranodal marginal zone lymphoma of the central nervous system (CNS EMZBL) is a rare disease. We present a review of the literature and describe its presentation, differential diagnosis, treatment options, and outcomes. Systematic search of PubMed, Medline, and Embase databases via the Ovid engine for primary articles and case reports yielded 37 unduplicated peer-reviewed articles of CNS EMZBL. We identified 69 cases in these articles and 1 unreported case at our institution, which were included for this review's analysis...
September 23, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29099480/prolonged-lymphocytopenia-after-bendamustine-therapy-in-patients-with-relapsed-or-refractory-indolent-b-cell-and-mantle-cell-lymphoma
#10
H Saito, D Maruyama, A M Maeshima, S Makita, H Kitahara, K Miyamoto, S Fukuhara, W Munakata, T Suzuki, Y Kobayashi, H Taniguchi, K Tobinai
This corrects the article DOI: 10.1038/bcj.2015.86.
November 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/29094771/indolent-waxing-and-waning-cutaneous-presentation-of-htlv-1-associated-adult-t-cell-leukemia-lymphoma-in-an-hiv-1-positive-patient
#11
Justin D Richey, Benjamin J Chen, April C Deng
It is well known that patients infected with human immunodeficiency virus type I (HIV-1) are more likely to develop malignancies such as Kaposi sarcoma, non-Hodgkin lymphoma, and anal and cervical carcinomas.
November 2, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29081255/randomized-phase-ii-study-of-a-bendamustine-monotherapy-schedule-for-relapsed-or-refractory-low-grade-b-cell-non-hodgkin-lymphoma-or-mantle-cell-lymphoma-rabbit-14
#12
Kuniaki Itoh, Tadahiko Igarashi, Hiroyuki Irisawa, Nobuyuki Aotsuka, Shinichi Masuda, Yoshikazu Utsu, Hideki Tsujimura, Kunihiro Tsukasaki, Hisashi Wakita
The aim of this randomized phase II study was to improve the treatment delays and discontinuations associated with bendamustine use by comparing the effect of Benda-14 (intravenous bendamustine, 120 mg/m(2) on days 1 and 15, repeated every 4 weeks for a total of 6 cycles) with those of the standard treatment in relapsed indolent lymphoma and/or mantle cell lymphoma. Forty-six patients were randomly assigned to the treatments from September 2012 to February 2016. Treatment accomplishment rate and median relative dose intensity were similar in both arms: 38 and 63...
October 30, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29081245/primary-cutaneous-plasmablastic-lymphoma-in-an-immunocompetent-patient-is-it-associated-with-an-indolent-course
#13
Brady E Beltran, Pilar Quiñones, Gadwyn Sanchez, Antonio Paredes, Celia Moises, Esther Cotrina, Carlos A Torres-Cabala, Roberto N Miranda, Jorge J Castillo
No abstract text is available yet for this article.
October 30, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29081197/-clinical-features-and-prognosis-of-17-patients-with-primary-cold-agglutinin-disease
#14
Y Y Wu, X X Cao, H Cai, L Zhang, D B Zhou, J Li
Objective: To explore the clinical characteristics, treatment and prognosis in 17 patients with primary cold agglutinin disease (CAD) . Methods: Clinical data, treatment and survival status of 17 patients diagnosed with primary cold agglutinin disease in Peking Union Medical College Hospital during April 2007 to October 2016 were retrospectively analyzed. The MYD88(L265P) mutation was tested in 4 patients. Results: The median age of 17 patients was 67 years (range, 51-86 years) , and male- to female ratio was 1...
September 14, 2017: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29072952/primary-cutaneous-acral-cd8-t-cell-lymphoma
#15
REVIEW
Vivian M Hathuc, Alexandra C Hristov, Lauren B Smith
Primary cutaneous acral CD8(+) T-cell lymphoma is a new provisional entity in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. This is a challenging diagnosis because of its rarity, as well as its morphologic and immunophenotypic overlap with other CD8(+) cytotoxic lymphoid proliferations. Appropriate classification of this entity is crucial because of its indolent clinical behavior compared with other CD8(+) T-cell lymphomas. Knowledge of the clinical setting, sites of involvement, and morphologic features can aid in correct diagnosis...
November 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29070613/copanlisib-produces-prolonged-responses-in-lymphoma
#16
(no author information available yet)
A phase II trial of the pan-class I PI3K inhibitor copanlisib demonstrated that it induces objective responses in 59% of patients with relapsed or refractory indolent lymphoma. The responses lasted a median of 22.6 months. Although the drugs weren't compared head to head, researchers suspect that the side effects of copanlisib may be less severe than those of idelalisib, another PI3K inhibitor.
October 25, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29069998/composite-small-lymphocytic-lymphoma-chronic-lymphocytic-leukemia-and-follicular-lymphoma-a-clinicopathological-study-of-six-cases
#17
Fatima Zahra Jelloul, Qiang Hua Chen, Tianyu Yang, Nina Haghi, Judith Brody, Xinmin Zhang, Silvat Sheikh-Fayyaz
BACKGROUND: Composite small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and follicular lymphoma (FL) is extremely rare, and only 13 cases have been reported previously. METHODS: We identified 6 cases of composite SLL/CLL and FL in our database and studied their clinical, histologic, immunophenotypic, and cytogenetic features. A literature review of the existing cases was also conducted. RESULTS: The patients included 4 males and 2 females, with a median age of 72 years...
October 1, 2017: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29067930/granulomatous-slack-skin-syndrome-report-of-a-unique-case
#18
S Uma Maheswari, V Sampath, A Ramesh
Granulomatous slack skin syndrome is a rare variant of cutaneous T-cell lymphoma (mycosis fungoides). It is characterized clinically by redundant skin folds, which show a predilection towards flexural areas such as the axilla and the groin. Histologically, it shows a granulomatous T-cell infiltrate and loss of elastic tissue. It has an indolent but progressive course; and is usually refractory to treatment. We report a unique case of slack skin syndrome, sparing the classical sites with rapid and unusual involvement of non-intertriginous areas...
August 28, 2017: Indian Journal of Dermatology, Venereology and Leprology
https://www.readbyqxmd.com/read/29063983/retrospective-analysis-of-first-line-treatment-for-follicular-lymphoma-based-on-outcomes-and-medical-economics
#19
Manaka Muneishi, Ayaka Nakamura, Katsumi Tachibana, Junko Suemitsu, Shinji Hasebe, Kazuto Takeuchi, Yoshihiro Yakushijin
BACKGROUND: Follicular lymphoma (FL) is the most common type of non-Hodgkin lymphoma (NHL), with indolent progression. Several treatment options are selected, based not only on disease status, quality of life (QOL), and age of patient, but also on recent increasing medical costs. We retrospectively analysed the first-line treatment of FL with regard to treatment outcomes and medical economics, and discuss the appropriate strategies for FL. METHODS: Data on a total of 69 newly-diagnosed patients with FL was retrospectively collected from 2001 to 2015...
October 24, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29057463/alk-positive-primary-cutaneous-anaplastic-large-cell-lymphoma-a-case-report-and-review-of-the-literature
#20
REVIEW
Shamir Geller, Theresa N Canavan, Melissa Pulitzer, Alison J Moskowitz, Patricia L Myskowski
Anaplastic large cell lymphoma (ALCL) limited to the skin is a distinct disease that is designated primary cutaneous ALCL (pcALCL). It has an indolent course with a significantly better prognosis compared to systemic ALCL (sALCL). Anaplastic lymphoma kinase (ALK) expression in lesions of cutaneous ALCL is classically considered to be a marker for skin involvement by sALCL. However, recent reports of patients with ALK-positive pcALCL challenge this concept and raise prognostic and therapeutic dilemmas. Herein, we report a case of ALK-positive pcALCL in a 45-year-old woman who was treated with local radiotherapy...
October 23, 2017: International Journal of Dermatology
keyword
keyword
99818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"